An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs PRX 106 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Protalix Biotherapeutics
- 02 Jan 2018 According to a Protalix Biotherapeutics media release, the Company expects to report full results from this study by the end of the first quarter of 2018.
- 02 Jan 2018 Interim results (n=14) published in a Protalix Biotherapeutics media release.
- 29 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to a Protalix BioTherapeutics media trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History